My statement re: anti-competitive government rules is based on private conversations with direct insiders who have explained to me that the reason BRTX can’t raise the funds required to move forward is that the cost of obtaining FDA approval is an unbearable administrative burden that makes the final product too expensive to sell profitably. It matters nothing how well it works if consumers can’t afford it. The company has acknowledged this issue in its past annual reports. They were unable to overcome it 2017-2020 and there is even less reason to think they can do so now with a Democrat (death by regulation) President.
Agreed. No company is going to invest millions into a project to lose money. This day to day downward price movement has little to do with the long term valuation. So yes, buy, buy, buy.
News 
Market Data 
Discover 
